Table 1

Characteristics of patients in the study

Patient no.	Sex	Age (years)	Atopy	Nasal polyps	Asthma duration (years)	Aspirin intolerance duration (years)	Oral aspirin threshold dose (mg)	Inhaled lysine aspirin threshold concentration (mg/ml)	Treatment	Asthma severity grade (GINA)
1	F	50	Yes	Yes	12	3	20		ICS, STP	4
2	F	48	Yes	No	15	11		180	ICS, STP	2
3	F	48	Yes	Yes	1	1		45	STP	2
4	M	48	Yes	Yes	2	2		90	ICS, NCS, STP	3
5	M	26	Yes	Yes	9	7	150		ICS, NCS, DSCG, STP, LAB	2
6	F	64	Yes	Yes	21	21	100		ICS, STP	2
7	F	45	Yes	Yes	15	14	80		ICS,	2
8	F	59	Yes	Yes	21	15	150		ICS, STP	2
9	F	33	Yes	Yes	11	11	10		ICS,	3
10	F	57	Yes	No	32	27	30		STP	3
11	F	68	No	No	1	1		22.5	ICS, STP	3
12	F	51	Yes	No	8	4	60		ICS, OCS, STP, NS, KET	4
13	M	48	Yes	No	16	11	80		ICS, NCS	3
14	F	62	No	No	16	13	60		ICS, OCS, STP	4
15	F	67	No	Yes	3	1		180	ICS, NCS, STP	3
16	M	43	Yes	Yes	4	2	40		ICS, STP, AST	3
17	F	41	Yes	No	12	10	60		ICS, NCS, STP	3
Mean (SD)		50.5 (11.5)			11.7 (8.4)	9.1 (7.6)				2.82 (0.73)

ICS = inhaled corticosteroids; OCS = oral corticosteroids; NCS = nasal corticosteroids; STP = sustained release theophylline preparations; DCSG = disodium cromoglycate; NS = nedocromil sodium; KET = ketotifen fumarate; AST = astemizol; LAB = long acting β₂ mimetic.